Tumor Treating Fields
Tumor Treating Fields is novel cancer treatment therapy using alternating electric field to disturb the rapid cell division exhibited by cancer cells. The system was developed by Novocure company and was approved by the US FDA on April 15, 2011 for the treatment of recurrent Glioblastoma Multiforme, a type of malignant brain tumor. It is undergoing clinical trials for its effectiveness in the treatment of newly diagnosed glioblastoma multiforme (GBM) and lung cancer. The National Comprehensive Cancer Network recently updated their Guidelines for the treatment of recurrent Glioblastoma Multiforme  to include, as an option, Tumor Treating Fields.
- Kirson et al. (2004). "Disruption of Cancer Cell Replication by Alternating Electric Fields". Cancer Research 64.
- Kirson et al. (2007). "Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors". PNAS 104.
- Stupp et al. (2010). "A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma.". Journal of Clinical Oncology 28.
- Kirson et al. (2010). "A phase II study of tumor treating fields (TTFields) in combination with pemetrexed for advanced non small cell lung cancer (NSCLC)". Ann Oncol 64.
- Novocure website
- Treating cancer with electric fields Bill Doyle TED talk
- Can an Electric Hat Fight Tumors? comment in Science
- TTF and chemotherapy increase survival for patients with advanced non-small cell lung cancer comment in PhysOrg
- Alternating electric fields disrupt glioblastoma tumor growth in pilot study comment in Nature Clinical Practice Neurology
- NCCN Guidelines NCCN Guidelines for CNS cancers.
|This medical article is a stub. You can help Wikipedia by expanding it.|